Market Access News | pharmaphorum

News

FDA finds no link between GLP-1 drugs and suicide

The FDA has given an update on its ongoing review of a possible link between GLP-1 agonist drugs used to treat diabetes and obesity and suicide, saying it can find no evid

News

FDA starts review of Lantheus’ generic Lutathera

Lantheus has filed what it says is the first generic version of Novartis’ big-selling cancer radionuclide therapy Lutathera in the US, used to treat rare neuroendocrine tu

News

NICE expands access to Paxlovid amid over-supply

NICE has extended the number of patients eligible for treatment with Pfizer’s oral antiviral Paxlovid by around 1.4 million, as millions of doses of the COVID-19 therapy a

News

FDA clears French syphilis drug imports to tackle shortage

Facing a sharp rise in the number of syphilis cases, the FDA has authorised the importation from France of a life-saving drug for the sexually transmitted infection (STI)

News

CHMP calls in advisors to assist in Leqembi review

Eisai and Biogen’s marketing application for Alzheimer’s disease therapy Leqembi will face an independent advisory committee convened by the EMA before a decision is made

News

Stada, Alvotech get first EU approval for biosimilar Stelara

Johnson & Johnson’s blockbuster immunology drug Stelara is facing its first approved biosimilar in Europe, which is due to launch after the drug loses EU patent protection in July

FDA finds no link between GLP-1 drugs and suicide

FDA starts review of Lantheus’ generic Lutathera

NICE expands access to Paxlovid amid over-supply

FDA clears French syphilis drug imports to tackle shortage

CHMP calls in advisors to assist in Leqembi review

Stada, Alvotech get first EU approval for biosimilar Stelara

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks